Cartesian Therapeutics (RNAC) News Today $12.70 +0.43 (+3.50%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$12.72 +0.03 (+0.20%) As of 05/2/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period 683 Capital Management LLC Has $2.24 Million Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)683 Capital Management LLC grew its holdings in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 65.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,000 shares of the company's stock aftMay 4 at 7:14 AM | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 2 at 7:05 AM | globenewswire.comBrokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Price Target at $42.67April 30, 2025 | americanbankingnews.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC raised its stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 63.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 221,257 shares of the company's stock after purchasing an additional 85,557 shares during the perioApril 29, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average rating of "Moderate Buy" by the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six haveApril 27, 2025 | marketbeat.comCartesian Therapeutics management to meet with BTIGApril 26, 2025 | markets.businessinsider.comJPMorgan Chase & Co. Sells 34,278 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC)JPMorgan Chase & Co. reduced its position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 11.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,740 shares of the company's stock after selling 34,278 sharesApril 21, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC reissued a "buy" rating and issued a $41.00 price target on shares of Cartesian Therapeutics in a report on Wednesday.April 11, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Cartesian Therapeutics in a report on Wednesday.April 11, 2025 | marketbeat.com1RNAC : Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In...April 9, 2025 | benzinga.comMizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)April 9, 2025 | markets.businessinsider.comCartesian Therapeutics Shares Rise on Positive Phase 2b Trial ResultsApril 8, 2025 | marketwatch.comCartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis TrialApril 8, 2025 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 2, 2025 | globenewswire.comCartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by AnalystsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the compaApril 1, 2025 | marketbeat.comSubstantial Insider Buying: American Express, Asana, and MoreMarch 30, 2025 | 247wallst.comTimothy Springer Spends US$1.4m On Cartesian Therapeutics StockMarch 23, 2025 | finance.yahoo.comAnalysts Set Expectations for RNAC FY2025 EarningsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for Cartesian Therapeutics in a report issued on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($3.65) per share for the year. CaMarch 20, 2025 | marketbeat.comOppenheimer Reaffirms Their Hold Rating on Cartesian Therapeutics (RNAC)March 17, 2025 | markets.businessinsider.comErste Asset Management GmbH Has $3.26 Million Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Erste Asset Management GmbH lowered its stake in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 93.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 173,566 shares of the company's stock after selling 2,527,000 shares during the peMarch 16, 2025 | marketbeat.comCartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 16, 2025 | finanznachrichten.deHC Wainwright Issues Pessimistic Forecast for Cartesian Therapeutics (NASDAQ:RNAC) Stock PriceHC Wainwright reduced their target price on Cartesian Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a report on Friday.March 15, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC restated a "buy" rating and set a $41.00 price objective on shares of Cartesian Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comCartesian Therapeutics Advances mRNA Therapy PipelineMarch 14, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and ProQR (PRQR)March 14, 2025 | markets.businessinsider.comCartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | finance.yahoo.comTD Cowen Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)March 13, 2025 | markets.businessinsider.comCartesian Therapeutics announces employment inducement grantMarch 6, 2025 | markets.businessinsider.comCartesian Therapeutics Announces New Employment Inducement GrantMarch 6, 2025 | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and eight have assigned a buy ratingMarch 6, 2025 | marketbeat.comCartesian Therapeutics (RNAC) Projected to Post Earnings on ThursdayCartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comCartesian Therapeutics to Participate in Upcoming Investor ConferencesFebruary 18, 2025 | globenewswire.comFY2024 Earnings Forecast for RNAC Issued By Leerink PartnrsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Cartesian Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will postFebruary 10, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from AnalystsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has earned an average rating of "Moderate Buy" from the ten brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation toFebruary 9, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for RNAC FY2029 Earnings?Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Cartesian Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will poFebruary 7, 2025 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsFebruary 6, 2025 | globenewswire.comPromising Developments and Strategic Expansion Bolster Buy Rating for Cartesian TherapeuticsJanuary 29, 2025 | markets.businessinsider.comStrong Outlook for Cartesian Therapeutics: FDA SPA Agreement and Positive Phase 2b Results Boost Confidence in Descartes-08January 28, 2025 | markets.businessinsider.comBuy Rating for Cartesian Therapeutics: Promising Phase 3 Prospects for Descartes-08 in Treating Myasthenia GravisJanuary 28, 2025 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $45.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday.January 28, 2025 | marketbeat.comCartesian Therapeutics announces FDA SPA agreement for Phase 3 AURORA trialJanuary 27, 2025 | markets.businessinsider.comNeedham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC reissued a "buy" rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research note on Monday.January 27, 2025 | marketbeat.comCartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia GravisJanuary 27, 2025 | globenewswire.comCartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA TherapiesJanuary 17, 2025 | seekingalpha.comPromising Developments and Strategic Milestones Drive Buy Rating for Cartesian TherapeuticsJanuary 15, 2025 | markets.businessinsider.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have issuedJanuary 15, 2025 | marketbeat.comCartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune DiseasesJanuary 13, 2025 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comCartesian Therapeutics announces employment inducement grantsJanuary 8, 2025 | markets.businessinsider.com Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address RNAC Media Mentions By Week RNAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAC News Sentiment▼0.940.73▲Average Medical News Sentiment RNAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAC Articles This Week▼43▲RNAC Articles Average Week Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CALT News Today IOVA News Today AMPH News Today SNDX News Today ADPT News Today BGM News Today AUPH News Today ETNB News Today WVE News Today XFOR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAC) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
